Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons

Jared M. Baeten, Jairam Lingappa, Ingrid Beck, Lisa M. Frenkel, Gregory Pepper, Connie Celum, Anna Wald, Kenneth Fife, Edwin Were, Nelly Mugo, Jorge Sanchez, Myron Essex, Joseph Makhema, James Kiarie, Carey Farquhar, Lawrence Corey

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.

Original languageEnglish
Pages (from-to)117-121
Number of pages5
JournalJournal of Infectious Diseases
Volume203
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

valacyclovir
Human Herpesvirus 2
Acyclovir
HIV-1
Botswana
Therapeutics
Peru
Kenya
RNA-Directed DNA Polymerase
Codon
Confidence Intervals
Mutation

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. / Baeten, Jared M.; Lingappa, Jairam; Beck, Ingrid; Frenkel, Lisa M.; Pepper, Gregory; Celum, Connie; Wald, Anna; Fife, Kenneth; Were, Edwin; Mugo, Nelly; Sanchez, Jorge; Essex, Myron; Makhema, Joseph; Kiarie, James; Farquhar, Carey; Corey, Lawrence.

In: Journal of Infectious Diseases, Vol. 203, No. 1, 01.01.2011, p. 117-121.

Research output: Contribution to journalArticle

Baeten, JM, Lingappa, J, Beck, I, Frenkel, LM, Pepper, G, Celum, C, Wald, A, Fife, K, Were, E, Mugo, N, Sanchez, J, Essex, M, Makhema, J, Kiarie, J, Farquhar, C & Corey, L 2011, 'Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons', Journal of Infectious Diseases, vol. 203, no. 1, pp. 117-121. https://doi.org/10.1093/infdis/jiq013
Baeten, Jared M. ; Lingappa, Jairam ; Beck, Ingrid ; Frenkel, Lisa M. ; Pepper, Gregory ; Celum, Connie ; Wald, Anna ; Fife, Kenneth ; Were, Edwin ; Mugo, Nelly ; Sanchez, Jorge ; Essex, Myron ; Makhema, Joseph ; Kiarie, James ; Farquhar, Carey ; Corey, Lawrence. / Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. In: Journal of Infectious Diseases. 2011 ; Vol. 203, No. 1. pp. 117-121.
@article{5f3f18ea917846e4af0eaf7c2e6d185f,
title = "Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons",
abstract = "Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95{\%} confidence interval, 0{\%}-2.2{\%}). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.",
author = "Baeten, {Jared M.} and Jairam Lingappa and Ingrid Beck and Frenkel, {Lisa M.} and Gregory Pepper and Connie Celum and Anna Wald and Kenneth Fife and Edwin Were and Nelly Mugo and Jorge Sanchez and Myron Essex and Joseph Makhema and James Kiarie and Carey Farquhar and Lawrence Corey",
year = "2011",
month = "1",
day = "1",
doi = "10.1093/infdis/jiq013",
language = "English",
volume = "203",
pages = "117--121",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons

AU - Baeten, Jared M.

AU - Lingappa, Jairam

AU - Beck, Ingrid

AU - Frenkel, Lisa M.

AU - Pepper, Gregory

AU - Celum, Connie

AU - Wald, Anna

AU - Fife, Kenneth

AU - Were, Edwin

AU - Mugo, Nelly

AU - Sanchez, Jorge

AU - Essex, Myron

AU - Makhema, Joseph

AU - Kiarie, James

AU - Farquhar, Carey

AU - Corey, Lawrence

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.

AB - Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.

UR - http://www.scopus.com/inward/record.url?scp=79851488828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851488828&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiq013

DO - 10.1093/infdis/jiq013

M3 - Article

VL - 203

SP - 117

EP - 121

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -